Breaks Categories: News

WednesdayMay 08, 2024 2:16 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its second human pilot study, GLP-1-H24-2, is underway and the first dosing visit for all nine study participants has concluded. The three-arm, crossover study will compare three 7 mg semaglutide dose formulations: A positive control Rybelsus(R) swallowed tablet (already dosed); DehydraTECH-semaglutide swallowed capsules; and, for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. According to the announcement, the second DehydraTECH study arm will use a Rybelsus(R) composition processed with DehydraTECH that is compliant with the U.S. Food and Drug Administration’s Inactive Ingredient Database…

Continue Reading

MondayMay 06, 2024 3:15 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 Drugs

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced an applied research program to evaluate certain molecular characteristics of DehydraTECH processed with the glucagon-peptide 1 (“GLP-1”) drug, semaglutide, related to its mode of action and performance. According to the announcement, the research will be conducted in partnership with the National Research Council of Canada (“NRC”). “We are excited about our partnership with the NRC for the mode of action molecular characterization of DehydraTECH-GLP-1 drugs. This work program could potentially provide data to assist Lexaria’s efforts in partnering with the pharmaceutical industry for the most rapid…

Continue Reading

WednesdayMay 01, 2024 3:50 pm

CannabisNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Responds to Announcement Rescheduling of Marijuana by DEA

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ), a holding company focused in the cannabis and agricultural technology sectors, released an official reaction to the “historic milestone” in the cannabis industry as the U.S. Drug Enforcement Administration (“DEA”) moves to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act (“CSA:). The reclassification was fueled by a recommendation from the U.S. Department of Health and Human Services and represents a notable change in U.S. drug policy. According to the announcement from MedCana, cannabis has been unjustly categorized as a Schedule I substance alongside heroin and LSD for…

Continue Reading

WednesdayMay 01, 2024 2:19 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces $4.7M Warrant Exercise Agreement

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has entered into a warrant exercise agreement with an existing accredited investor to exercise in full existing warrants. Specifically, the agreement is comprised of the purchase of 2,917,032 shares of common stock, as to 1,618,330 warrants exercised at an exercise price of $0.97 per share, and 1,298,702 warrants exercised at $2.185 per share; the shares and warrants were originally issued in October 2023 and February 2024, respectively. The company noted that following this exercise, there are no remaining warrants exercisable at $0.97 and 259,741 warrants unexercised at $2.185. According…

Continue Reading

MondayApr 29, 2024 2:42 pm

CannabisNewsBreaks – Golden Triangle Ventures Inc. (GTVH) CEO Featured Guest in Most Recent Bell2Bell Podcast

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, is spotlighted in the latest episode of the Bell2Bell Podcast, released from IBN. During the interview, GTVH president and CEO Steffan Dalsgaard talks with Bell2Bell host Stuart Smith about the company and Destino Ranch, its flagship project designed to be a tourist attraction, large immersive art installation and music festival venue; the ranch will be located about an hour from Las Vegas. As part of the development, Golden Triangle Ventures has purchased 70 acres and acquired ABI Create, one of the largest event developers in the country. In addition, Dalsgaard noted…

Continue Reading

ThursdayApr 25, 2024 1:01 pm

CannabisNewsBreaks – Golden Triangle Ventures Inc. (GTVH), Subsidiary Establish Four-Pillar Business Model to Ensure Successful Development of Destino Ranch

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, and its wholly owned subsidiary, Lavish Entertainment (or “Lavish”), have developed a comprehensive four-pillar business model. According to the announcement, the company intends for this key business component to be a critical component moving forward as Lavish Entertainment focuses on creating an industry-leading entertainment business. Specifically, the business model will be used as the company’s flagship project, Destino Ranch, is being developed. The new business model includes four essential key foundational elements: logistics, staffing, equipment and production. The company noted that these specific pillars were carefully identified and organized to complement…

Continue Reading

WednesdayApr 24, 2024 2:52 pm

CannabisNewsBreaks – Software Effective Solutions Corp.’s (SFWJ) Eko2o S.A.S. Marks Significant Step in Strategy to Increase Global Footprint

Eko2o S.A.S., a pioneering force in agricultural technology and infrastructure and a majority-controlled subsidiary of Software Effective Solutions (OTC: SFWJ) (d/b/a MedCana), today announced its continued growth and expansion as a key infrastructure supplier for some of Colombia’s largest flower producers. In addition, the company announced it is enhancing its support and sales operations with international partnerships, notably with Danziger International, one of the flower industry’s most respected names. According to the announcement, the expanding partnership with Danziger International marks a significant step in Eko2o’s strategy to increase its global footprint and is expected to boost Eko2o’s visibility on the…

Continue Reading

TuesdayApr 23, 2024 2:33 pm

CannabisNewsBreaks – Zoned Properties Inc. (ZDPY) Announces $1M Stock Repurchase Program

Zoned Properties (OTCQB: ZDPY), a leading real estate development firm for emerging and highly regulated industries including legalized cannabis, today announced that its board of directors has approved a share repurchase program, pursuant to which the company is authorized to purchase up to $1 million of its common stock over an unlimited time period. “As our business continues to outperform in a challenging overall operating environment, we are thrilled to announce this share repurchase program. The approval of this program demonstrates the management team’s and board’s confidence in our prospects for the future, ongoing operational strength and sound capital structure,”…

Continue Reading

ThursdayApr 18, 2024 2:18 pm

CannabisNewsBreaks – Zoned Properties Inc. (ZDPY) Featured in Bell2Bell Podcast

Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company for emerging and highly regulated industries, was featured in the latest episode of the Bell2Bell Podcast as part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Bryan McLaren, chairman and CEO of Zoned Properties, joined the program to provide an overview of the company’s business model and how his experience translates into the regulated cannabis space. “Zoned Properties, based in Scottsdale, Arizona, is focused on real estate and the regulated cannabis industry. Zoned Properties is essentially a technology-driven property investment company. We look at state-by-state markets…

Continue Reading

ThursdayApr 18, 2024 1:56 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Welcomes Leading Authority in Alzheimer’s Research to Scientific Advisory Board

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is announcing that Dr. David G. Morgan, PhD, a renowned leader in neurodegenerative disease, has joined its scientific advisory board (“SAB”). The announcement noted that the addition reinforces the company’s commitment to advancing its INM-901 program in the treatment of Alzheimer’s disease. Dr. Morgan is the Director of the Alzheimer’s Alliance and MSU Foundation Professor of Translational Neuroscience at Michigan State University. His research interests are Alzheimer’s disease, aging and brain function. “We are privileged to welcome someone of Dr. Morgan’s…

Continue Reading